



# CERTIFICATE OF COMPLETION

THE UNIVERSITY OF WASHINGTON AND NATIONAL HIV CURRICULUM CERTIFY THAT

*Cesar Mendez, MPH*

HAS COMPLETED THE FOLLOWING QUESTION BANK TOPICS IN THE

## NATIONAL HIV CURRICULUM QUESTION BANK 1<sup>ST</sup> EDITION

Acute and Recent HIV Infection, Cutaneous Manifestations, Epidemiology of HIV, HIV Diagnostic Testing, HIV Screening Recommendations, Initial Evaluation, Linkage to HIV Care, Oral Manifestations, Preventing Perinatal HIV Transmission, Primary Care Management, Screening for Mental Health Conditions, and Substance Use Disorders

A handwritten signature in black ink, reading "David H. Spach, MD".

David H. Spach, MD

Editor-in-Chief, National HIV Curriculum

Professor of Medicine, University of Washington

The Infectious Diseases Education & Assessment (IDEA) Program created and manages this federally-funded curriculum.

This certificate shows the progress of **Cesar Mendez, MPH**, a Physician, identified by **melc.cesar@gmail.com** as of June 29, 2025, 3:39 pm.  
You may validate this certificate or obtain a digital copy by visiting <https://www.hiv.uw.edu/certificate/question-bank/melc.cesar@gmail.com/1>

**The following Question Bank Topics were completed with a score of 80% or higher:**

Question Bank Topics	Learning Objective
<b>Acute and Recent HIV Infection</b> 10 questions, Completed November 17, 2019	<ul style="list-style-type: none"> <li>• Explain the immunopathogenesis, clinical manifestations, and diagnosis of acute HIV infection</li> <li>• List the potential public health benefits of diagnosing and treating a person with acute and recent HIV infection</li> <li>• Summarize the recommended antiretroviral treatment regimens for persons with acute or recent HIV infection</li> </ul>
<b>Cutaneous Manifestations</b> 10 questions, Completed November 25, 2019	<ul style="list-style-type: none"> <li>• Recognize common HIV-related cutaneous manifestations and list appropriate diagnostic procedures when indicated</li> <li>• Describe the etiologies of cutaneous findings in persons with HIV, including adverse drug reaction, immune dysregulation, infection, or immune reconstitution syndrome.</li> <li>• Define appropriate treatment for common dermatological manifestations</li> </ul>
<b>Epidemiology of HIV</b> 15 questions, Completed November 11, 2019	<ul style="list-style-type: none"> <li>• Explain the difference between HIV prevalence and incidence</li> <li>• Describe the contemporary epidemiology of HIV-1 in the United States</li> <li>• Discuss the impact of racial/ethnic disparities and social determinants on HIV epidemiology</li> <li>• Identify populations in the United States at risk for HIV-2</li> <li>• Summarize the global HIV epidemiology</li> </ul>
<b>HIV Diagnostic Testing</b> 10 questions, Completed November 14, 2019	<ul style="list-style-type: none"> <li>• Compare different types of HIV diagnostic tests and when to use these tests</li> <li>• Explain updated recommended nomenclature for HIV diagnostic tests</li> <li>• Summarize the CDC/APHL recommended HIV testing algorithm</li> <li>• Discuss interpretation of HIV diagnostic tests and delivery of test results to clients</li> </ul>
<b>HIV Screening Recommendations</b> 10 questions, Completed November 11, 2019	<ul style="list-style-type: none"> <li>• Explain the rationale for routine HIV screening and identify strategies to overcome potential barriers to routine screening</li> <li>• Discuss current Centers for Disease Control and Prevention (CDC) and United States Preventive Services Task Force (USPSTF) screening recommendations for HIV-1 and HIV-2 in the United States</li> </ul>
<b>Initial Evaluation</b> 15 questions, Completed November 20, 2019	<ul style="list-style-type: none"> <li>• Describe the goals and components of the initial evaluation of persons with HIV who are entering, reentering, or transferring care</li> <li>• Categorize the different stages of HIV disease and the criteria used to define each stage</li> <li>• List recommendations for the initial monitoring visit and baseline laboratory tests</li> </ul>
<b>Linkage to HIV Care</b> 5 questions, Completed November 18, 2019	<ul style="list-style-type: none"> <li>• Summarize current estimated HIV linkage to care data in the United States.</li> <li>• Describe strategies for optimizing linkage to care for persons newly diagnosed with HIV in the United States</li> <li>• Identify barriers for linking persons newly diagnosed to care</li> <li>• List the metrics used to estimate and monitor linkages to care</li> </ul>
<b>Oral Manifestations</b> 10 questions, Completed November 23, 2019	<ul style="list-style-type: none"> <li>• Recognize common oral manifestations in persons with HIV and list appropriate diagnostic procedures when indicated</li> <li>• List three types of oral candidiasis manifestations</li> <li>• Define appropriate treatment for common oral manifestations</li> </ul>

Question Bank Topics	Learning Objective
<b>Preventing Perinatal HIV Transmission</b>  20 questions, Completed November 10, 2019	<ul style="list-style-type: none"> <li>• Explain the mechanisms of perinatal HIV transmission and interventions to reduce the risks of perinatal HIV transmission</li> <li>• Discuss interventions to reduce intrapartum perinatal HIV transmission</li> <li>• Describe recommended antiretroviral prophylaxis for infants born to women living with HIV infection</li> <li>• Summarize recommendations for initial management of infants exposed to HIV, including HIV diagnostic testing, monitoring, and Pneumocystis pneumonia prophylaxis</li> </ul>
<b>Primary Care Management</b>  15 questions, Completed February 17, 2020	<ul style="list-style-type: none"> <li>• Discuss the monitoring and management of hypertension and hyperlipidemia in persons with HIV, including integration of risk reduction strategies</li> <li>• Explore special considerations in the management of diabetes mellitus in persons with HIV</li> <li>• Review causes and management of renal disease in persons with HIV</li> <li>• Describe screening indications and management of osteoporosis in persons with HIV</li> <li>• Explain the relationship between obstructive lung disorders and HIV, and list options for tobacco cessation</li> <li>• Summarize cancer screening recommendations in persons with HIV</li> </ul>
<b>Screening for Mental Health Conditions</b>  5 questions, Completed February 19, 2020	<ul style="list-style-type: none"> <li>• Summarize common screening tools for mental health conditions, including screening tools for neurocognitive disorders</li> <li>• Discuss how to integrate screening tools for mental health conditions into primary care HIV clinical practice</li> <li>• Identify the relationships between specific mental health conditions and HIV acquisition and transmission risk</li> <li>• Explain the association between major depression and increased risk for mortality in persons with HIV and identify treatment options for depression</li> <li>• Describe models for integrating mental health care with HIV care, including through referral, consultation, co-located services and the use of embedded mental health providers</li> </ul>
<b>Substance Use Disorders</b>  10 questions, Completed March 8, 2020	<ul style="list-style-type: none"> <li>• Summarize screening for substance use disorders in persons with HIV</li> <li>• List options for treatment of tobacco dependence</li> <li>• Compare approaches for managing persons with alcohol use disorder</li> <li>• Describe the approach to management of persons with stimulant use disorder</li> <li>• Discuss strategies for the management of opioid use disorder</li> </ul>